07:00 , Oct 20, 2014 |  BC Week In Review  |  Company News

Asterand Bioscience, ReproCell deal

ReproCell acquired the induced pluripotent stem cell (iPSC) reagents and services business of Stemgent Inc. , now known as Asterand Biosciences Inc., for about $8.5 million in cash. Asterand will now focus on its human...
07:00 , Aug 6, 2012 |  BC Week In Review  |  Company News

BioSeek, Stemgent deal

BioSeek, formerly Asterand plc , completed the sale of its non-BioSeek Tissue Based Solutions business to Stemgent for $9 million in cash (see BioCentury, July 23). BioSeek plc (LSE:ATD), Royston, U.K.   Stemgent Inc. ,...
07:00 , Jul 23, 2012 |  BC Week In Review  |  Company News

Asterand, Stemgent deal

In June, Stemgent said it will acquire Asterand's non-BioSeek Tissue Based Solutions business for $9 million in cash. At the time, the company also proposed to delist its shares. In a July 13 shareholder circular,...
07:00 , May 26, 2011 |  BC Innovations  |  Strategy

iPS cells: Five years later

Despite the proliferation of technologies to derive induced pluripotent stem cells since they were first described five years ago, this has been a technology in search of a home. The tide may have finally turned....
07:00 , May 17, 2010 |  BC Week In Review  |  Company News

Miltenyi Biotec, Stemgent deal

Miltenyi received exclusive rights to commercialize Stemgent's existing stem cell product portfolio outside the U.S. Stemgent markets viral-delivered transcription factors, cell lines, antibodies, small molecules, matrices, cytokines, reagents and media for stem cell research. The...
08:00 , Mar 8, 2010 |  BC Week In Review  |  Financial News

Ubiquigent completes venture financing

Ubiquigent Ltd. , Dundee, U.K.   Business: Gene/Cell therapy   Date completed: 3/3/10   Type: Venture financing   Raised: £3 million ($4.5 million)   Investor: Stemgent Inc.   Note: Stemgent will make the investment over...
08:00 , Nov 16, 2009 |  BioCentury  |  Finance

Ebb & Flow

Although the terms of the acquisition of BioTrove Inc. by Life Technologies Corp. (NASDAQ:LIFE) haven't been undisclosed, the transaction could result in a more than 10X return over the next 12 months, according to investor...
07:00 , May 11, 2009 |  BC Week In Review  |  Company News

Fate Therapeutics, Stemgent deal

Fate and Stemgent established the Catalyst program to provide induced pluripotent stem (iPS) cell technology to the biotech and pharmaceutical industry in exchange for annual funding. Fate and Stemgent will jointly share expenses of the...
07:00 , May 19, 2008 |  BC Week In Review  |  Company News

Asterand board of directors update

Asterand plc (LSE:ATD), Royston, U.K.   Business: Functional genomics, ADMET, Supply/Service   Appointed: Ian Ratcliffe, president and CEO of Stemgent Inc.  ...